Observational Study of Adult Participants With Diabetic Macular Edema and Suboptimal Response to Anti-Vascular Endothelial Growth Factor Treated With Dexamethasone Intravitreal Implant

NCT ID: NCT05978622

Last Updated: 2025-08-05

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

327 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-10-30

Study Completion Date

2026-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The dexamethasone 700 μg intravitreal implant (DEX-I) delivers dexamethasone gradually to the retina over time. It is an approved drug for the treatment of DME. This study will assess adult participants with diabetic macular edema (DME) and suboptimal response to anti-vascular endothelial growth factor therapy that are treated with DEX-I in the routine clinical setting.

Approximately 327 participants who are prescribed DEX-I by their physicians will be enrolled at approximately 40 sites in approximately 10 countries globally.

Participants will be followed for 18 months post-DEX-I implantation according to the routine clinical practice of the prescribing centers. Only one eye per participant will be evaluated in the study.

No additional burden for participants in this trial is expected.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetic Macular Edema

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Dexamethasone Intravitreal Implant (DEX-I)

Dexamethasone 700 μg intravitreal implant (DEX-I) administered according to general clinical practice.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Participant diagnosed with DME in the study eye
* Study eye has received at least 3 and no more than 9 anti-VEGF injections in the 12 months prior to DEX-I initiation
* Study eye newly prescribed DEX-I. The prescribing decision lies with the physician and reflects their standard practice
* Participant showing a suboptimal response to anti-VEGF at Baseline in the study eye

Exclusion Criteria

* Any concomitant ocular or neurologic condition in the study eye that could cause macular edema or affect vision (except cataract)
* History of ocular surgery within 60 days of Baseline in the study eye
* History of Pan-Retinal Photocoagulation (PRP) or sectorial photocoagulation in the study eye in the 3 months prior to Baseline
* Significant media opacities in the study eye limiting Optical Coherence Tomography (OCT) quality
* Uncontrolled Ocular Hypertension (OHT) or advanced glaucoma in the study eye
* Active ocular inflammation in either eye
* Study eyes that are aphakic with Posterior Capsule Rent (PCR), Anterior Chamber Intraocular Lens (ACIOL), iris or scleral-fixed Intraocular Lens (IOL) or history of complicated cataract surgery with PCR
* Prior use of intravitreal corticosteroids in the study eye
* Patients with contraindications to DEX-I
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

AbbVie

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

ABBVIE INC.

Role: STUDY_DIRECTOR

AbbVie

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Uza /Id# 255831

Edegem, Antwerpen, Belgium

Site Status RECRUITING

CHU Saint Pierre /ID# 257650

Brussels, Brussels Capital, Belgium

Site Status COMPLETED

Universitair Ziekenhuis Brussel /ID# 255324

Jette, Brussels Capital, Belgium

Site Status RECRUITING

Ziekenhuis Oost-Limburg /ID# 255934

Genk, Limburg, Belgium

Site Status RECRUITING

Vitaz /Id# 265553

Sint-Niklaas, Oost-Vlaanderen, Belgium

Site Status COMPLETED

CHR de la Citadelle /ID# 257254

Liège, , Belgium

Site Status COMPLETED

Shenzhen Eye Hospital /ID# 262954

Shenzhen, Guangdong, China

Site Status RECRUITING

Tongji Hospital /ID# 270275

Wuhan, Hubei, China

Site Status RECRUITING

Xi'an Fourth Hospital /ID# 262972

Xi'an, Shaanxi, China

Site Status RECRUITING

Qingdao Eye Hospital Of Shandong First Medical University /ID# 262756

Qingdao, Shandong, China

Site Status RECRUITING

West China Hospital, Sichuan University /ID# 262745

Chengdu, Sichuan, China

Site Status RECRUITING

MVZ Augenzentrum am Berliner Ring /ID# 267412

Würzburg, Bavaria, Germany

Site Status RECRUITING

MVZ der Klinik Dardenne GmbH Makulazentrum /ID# 269798

Bonn, North Rhine-Westphalia, Germany

Site Status RECRUITING

Universitaetsklinikum Leipzig /ID# 255660

Leipzig, Saxony, Germany

Site Status RECRUITING

Augenzentrum Prinz 25 /ID# 261090

Augsburg, , Germany

Site Status RECRUITING

Dres. Schubert/Wissmann /ID# 261598

Ettlingen, , Germany

Site Status RECRUITING

Augenzentrum Frankfurt /ID# 255576

Frankfurt am Main, , Germany

Site Status RECRUITING

Augenzentrum Frohe Zukunft /ID# 256290

Halle, , Germany

Site Status RECRUITING

Augenzentrum am Johannisplatz /ID# 255754

Leipzig, , Germany

Site Status RECRUITING

University General Hospital Attikon /ID# 257957

Athens, Attica, Greece

Site Status RECRUITING

University General Hospital of Heraklion PA.G.N.I /ID# 258313

Heraklion, Crete, Greece

Site Status RECRUITING

University General Hospital of Alexandroupoli /ID# 275850

Alexandroupoli, Evros, Greece

Site Status RECRUITING

Eye Clinic of Athens /ID# 258749

Athens, , Greece

Site Status RECRUITING

General Hospital of Lamia /ID# 265442

Lamia, , Greece

Site Status RECRUITING

Reg Gen Univ Hosp Larissa /ID# 255235

Larissa, , Greece

Site Status RECRUITING

Opthalmica SA /ID# 258748

Thessaloniki, , Greece

Site Status RECRUITING

Papageorgiou General Hospital /ID# 265500

Thessaloniki, , Greece

Site Status RECRUITING

Rabin Medical Center /ID# 265476

Petah Tikva, Central District, Israel

Site Status RECRUITING

Kaplan Medical Center /ID# 265471

Rehovot, Central District, Israel

Site Status RECRUITING

Tel Aviv Sourasky Medical Center /ID# 265469

Tel Aviv, Tel Aviv, Israel

Site Status RECRUITING

Fondazione Policlinico Universitario Agostino Gemelli IRCCS-Università Cattolica /ID# 258134

Rome, Roma, Italy

Site Status RECRUITING

IRCCS Fondazione G.B. Bietti per lo studio e la ricerca in Oftalmologia- ONLUS /ID# 258039

Rome, Roma, Italy

Site Status RECRUITING

Universita Politecnica delle Marche - AOU Ospedali Riuniti di Ancona /ID# 258072

Ancona, , Italy

Site Status RECRUITING

Università di Torino /ID# 258442

Torino, , Italy

Site Status RECRUITING

ASU FC - P.O. Universitario Santa Maria della Misericordia /ID# 256293

Udine, , Italy

Site Status RECRUITING

Hospital de Santa Maria Maior, EPE /ID# 261063

Barcelos, Braga District, Portugal

Site Status RECRUITING

Unidade Local de Saude da Regiao de Leiria, EPE /ID# 262009

Leiria, , Portugal

Site Status RECRUITING

Centro Hospitalar do Baixo Vouga /ID# 264421

Porto, , Portugal

Site Status RECRUITING

Unidade Local de Saude de Santo Antonio, E.P.E. /ID# 262010

Porto, , Portugal

Site Status RECRUITING

Unidade Local de Saude do Estuario do Tejo, EPE /ID# 267945

Vila Franca de Xira, , Portugal

Site Status RECRUITING

National Taiwan University Hospital /ID# 262426

Taipei City, Taipei, Taiwan

Site Status RECRUITING

Kaohsiung Veterans General Hospital /ID# 262429

Kaohsiung City, , Taiwan

Site Status RECRUITING

Far Eastern Memorial Hospital /ID# 262428

New Taipei City, , Taiwan

Site Status RECRUITING

China Medical University Hospital /ID# 262427

Taichung, , Taiwan

Site Status RECRUITING

Linkou Chang Gung Memorial Hospital /ID# 256091

Taoyuan, , Taiwan

Site Status RECRUITING

Derriford Hospital and the Royal Eye Infirmary /ID# 260908

Plymouth, Devon, United Kingdom

Site Status RECRUITING

Gloucestershire Hospitals NHS Foundation Trust /ID# 256886

Cheltenham, Gloucestershire, United Kingdom

Site Status RECRUITING

Moorfields Eye Hospital /ID# 258465

London, Greater London, United Kingdom

Site Status RECRUITING

Royal Victoria Hospital /Id# 260232

Belfast, , United Kingdom

Site Status COMPLETED

Bradford Teaching hospitals/ Bradford macular centre /ID# 260909

Bradford, , United Kingdom

Site Status COMPLETED

Liverpool Univeristy Hospitals NHS Foundation Trust /ID# 260230

Liverpool, , United Kingdom

Site Status RECRUITING

East Cheshire NHS Trust /ID# 270263

Macclesfield, , United Kingdom

Site Status RECRUITING

Sunderland Eye Infirmary /ID# 258466

Sunderland, , United Kingdom

Site Status RECRUITING

Great Western Hospital /ID# 258467

Swindon, , United Kingdom

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Belgium China Germany Greece Israel Italy Portugal Taiwan United Kingdom

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Andrew Shirlaw

Role: CONTACT

844-663-3742

Related Links

Access external resources that provide additional context or updates about the study.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

P23-380

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.